Abstract
TRI-999 is a HIV fusion inhibitory peptide designed to improve upon the efficacy and convenience of Enfuvirtide (ENF, Fuzeon), the first approved HIV entry inhibitor. Derived from a gp41 HR2 region partially overlapping the ENF sequence, TRI-999 is modified using a fatty acid conjugation strategy through a poly(ethylene glycol) (PEG) linker to maintain potency while achieving the desired PK. Synthetic route comparison, process development, and GMP manufacturing at the kilo scale of TRI-999 are reported.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
